Galacto-oligosaccharides as an anti-bacterial and anti-invasive agent in lung infections

• Published in: Biomaterials Vol. 283; p. 121461
• Main Authors: Cai, Yang, van Putten, Jos P.M., Gilbert, Myrthe S., Gerrits, Walter J.J., Folkerts, Gert, Braber, Saskia
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.04.2022
• Subjects: Airway inflammation; Animals; Anti-Bacterial Agents - pharmacology; Antibiotic adjuvant; Bacteria; Bactericidal effect; Carbohydrate-based biomaterials; Cattle; Humans; Intranasal drug delivery; Lung - metabolism; Mannheimia haemolytica; Oligosaccharides - metabolism; Oligosaccharides - pharmacology; Oligosaccharides - therapeutic use; Pneumonia; Respiratory pathogens; Intranasal drug delivery; Respiratory pathogens; Airway inflammation; Carbohydrate-based biomaterials; Antibiotic adjuvant; Bactericidal effect
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2022.121461

Emerging antimicrobial resistance in infections asks for novel intervention strategies. Galacto-oligosaccharides (GOS) might be attractive alternatives to antibiotics due to their anti-inflammatory and anti-adhesive properties. Mannheimia haemolytica is one of the major Pasteurellaceae associated with bovine lung infections. Using M. haemolytica, we demonstrated that GOS have the capacity to reduce bacterial viability and can be used as adjuvant to improve antibiotic efficacy. Using M. haemolytica-treated primary bronchial epithelial cells (PBECs) of calves, we identified the anti-adhesive and anti-invasive activities of GOS. The observed inhibition of cytokine/chemokine release and the prevention of airway epithelial barrier dysfunction in M. haemolytica-treated PBECs by GOS might be related to the downregulation of “toll-like receptor 4/nuclear factor-κB” pathway and the anti-invasive and anti-adhesive properties of GOS. Particularly, GOS lowered lipopolysaccharides- but not flagellin-induced cytokine/chemokine release in calf and human airway epithelial cells. Finally, we performed in vivo experiments in calves and demonstrated for the first time that intranasal application of GOS can relieve lung infections/inflammation and lower M. haemolytica positivity in the lungs without affecting clinical performance. These findings not only shed light on the anti-inflammatory mechanisms of GOS during lung infections, but GOS might also be a promising anti-bacterial agent for preventing (lung) infections. [Display omitted]